Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an injectable solution for intravenous use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to control seizure activity.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

Partial‑onset seizures: Reduces the frequency of seizure episodes in patients with epilepsy. Epilepsy (adjunctive therapy): Provides additional seizure control when added to existing antiepileptic regimens. Refractory focal epilepsy: Improves seizure control in patients who have not responded adequately to other treatments.

Common Side Effects: - Nausea: Mild to moderate gastrointestinal upset. - Dizziness: Transient sensation of light‑headedness. - Headache: Occasional mild to moderate pain. - Somnolence: Increased sleepiness or fatigue. - Blurred vision: Temporary visual disturbances. - Fatigue: Generalized lack of energy.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR interval prolongation or arrhythmias. - Severe rash: Including Stevens‑Johnson syndrome. - Hypersensitivity reactions: Anaphylaxis or angioedema. - Suicidal ideation: Emergence of depressive thoughts. - Hepatic dysfunction: Elevated liver enzymes or hepatitis. - Anaphylactic shock: Immediate severe allergic response.

Precautions should be observed when using Lacosamide.

Monitor cardiac function: Perform ECG to detect PR interval changes. Adjust dose in renal impairment: Reduce dosage in patients with severe renal dysfunction. Avoid abrupt discontinuation: Taper gradually to prevent seizure worsening. Use caution in hepatic disease: Monitor liver enzymes regularly. Pregnancy considerations: Use only if potential benefit outweighs unknown risks. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Lacosamide may interact with other medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers: May reduce lacosamide plasma levels. - Co‑administration with other sodium‑channel blockers: Increases risk of CNS depression. - Drugs that prolong PR interval (e.g., carbamazepine): Heightened cardiac conduction risk. - Concomitant use with certain antiepileptics (e.g., phenytoin): May alter seizure control.

Moderate Interactions (Monitor Closely): - Oral contraceptives: May reduce contraceptive effectiveness. - Alcohol: Can enhance dizziness and somnolence. - Warfarin: Potential alteration of INR values. - Antidepressants: May increase risk of suicidal thoughts. - Diuretics: Possible electrolyte disturbances affecting cardiac safety.